Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Ardea Biosciences Announces Positive Interim Phase 2a Results For Lead Gout Drug, RDEA594
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. The Phase 1 results, along with additional preclinical data, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
diet pills
2009 Recipient Of Minority Scholar Award Begins Clinical Research On Leukemia
Alejandro Gutierrez, MD, is the third recipient of the ASH-AMFDP grant, an award designed to help increase the number of underrepresented minority scholars in the field of hematology, and will begin his research into the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) this month. The award, the result of a partnership between the American Society of Hematology (ASH) and the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation, provides four years of support, including an annual stipend of up to $75,000 and an annual grant of more than $29,000 for research activities.
News of the day
Chicago Woman Dies Of Swine Flu After Giving Birth
The new H1N1 swine flu virus claimed the life of a 20-year old Chicago woman on Saturday, one day after giving birth to a baby via Cesarean
Diagnostics

New Democrat Coalition Proposes Independent Panel To Oversee Comparative Effectiveness Research

Members of the moderate New Democrat Coalition on Tuesday proposed legislation (HR 2502) that would establish a non-governmental, independent office to oversee research efforts to compare the effectiveness of medical treatments, CQ HealthBeat reports. The bill would create the Health Care Comparative Effectiveness Research Institute, which would use money remaining from the $1.1 billion included in the economic stimulus package for comparative effectiveness research and additional funding from fees on Medicare and private insurers. HCCERI would be overseen by a 21-member board -- appointed by the U.S. Comptroller General -- that would include HHS officials, patients, physicians, private insurers and others (Norman, CQ HealthBeat, 5/19). In contrast, a panel to oversee comparative effectiveness research established by a provision in the stimulus bill would be made up of government health experts (Mundy, "Washington Wire," Wall Street Journal, 5/19). According to CQ HealthBeat, some people have raised concerns that comparative effectiveness research funded by the stimulus bill would result in research that could be used to deny coverage for certain treatments and that cost would factor disproportionately in such decisions. Rep. Kurt Schrader (D-Ore.), who introduced the bill, said HCCERI"s goal would be to ensure that medical decisions remain between physicians and patients and that both doctors and patients have the most understandable information possible to make such decisions. HCCERI also would make public its methods for deciding which research projects to approve, as well as any links the institute has to industry, its research protocols and the names of researchers. HCCERI would accept public comment before creating new research guidelines, and all research would be subject to peer review. In addition, HCCERI in commissioning studies would take steps to account for differences in patients" gender, race, age and ethnicity (CQ HealthBeat, 5/19).Schrader said that the bill "will bring patients, along with health care providers, physicians and industry, to the decision-making process," adding, "By having a seat at the table, the American people will help drive the direction of research based on what is most important to them" ("Washington Wire," Wall Street Journal, 5/19). Rep. Allyson Schwartz (D-Pa.) said that New Democrats seek to lower costs and improve quality of care, so "the most important thing we can do is to incentivize innovation and to provide that information on the best practices and best interventions and get that information out to providers." Industry Reaction Tony Coelho -- chair of the Partnership To Improve Patient Care, which represents patients, physicians, advocacy groups and industry members such as the Pharmaceutical Research and Manufacturers of America -- endorsed the legislation but said that comparative effectiveness research could potentially restrict patients" ability to choose between different treatments. He added, "My concern as a patient is that cost containment will become the main goal" (CQ HealthBeat, 5/19). Merck also released a statement in support of the bill. However, Voices for Physicians, a group affiliated with the Center for American Progress, said physicians must be able to access comparative effectiveness information that has not been influenced by the drug, hospital or insurance industries ("Washington Wire," Wall Street Journal, 5/19). Schrader said that HCCERI would employ strict guidelines to curb conflicts of interest and industry bias (CQ HealthBeat, 5/19). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009